In summary, we studied the effects of CDK4/6 inhibitor in combination with endocrine therapy in HR+/HER2-low and HR+/HER2-0 breast cancer cell subtypes both in vitro and in vivo. This evidence concerns the gene ERBB2 and breast carcinoma.